Literature DB >> 10455300

Pharmacological characterization of nicotine-induced acetylcholine release in the rat hippocampus in vivo: evidence for a permissive dopamine synapse.

R T Reid1, G K Lloyd, T S Rao.   

Abstract

In this study, the mechanism of nicotine-induced hippocampal acetylcholine (ACh) release in awake, freely moving rats was examined using in vivo microdialysis. Systemic administration of nicotine (0.4 mg kg(-1), s.c.) increased the levels of ACh in hippocampal dialysates. The nicotine-induced hippocampal ACh release was sensitive to the pretreatment of neuronal nicotinic acetylcholine receptor (nAChR) antagonists mecamylamine (3.0 mg kg(-1), s.c.) and dihydro-beta-erythrodine (DHbetaE; 4.0 mg kg(-1), s.c.) as well as systemic administration of the dopamine (DA) D1 receptor antagonist SCH-23390 (R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzaz epine; 0.3 mg kg(-1), s.c.). Local perfusion of mecamylamine (100 microM), DHbetaE (100 microM) or SCH-23390 (10 microM) through microdialysis probe did not increase basal hippocampal ACh release. Hippocampal ACh release elicited by systemic administration of nicotine (0.4 mg kg(-1), s.c.) was antagonized by local perfusion of SCH-23390 (10 microM), but not by MEC (100 microM) or DHbetaE (100 microM). Direct perfusion of nicotine (1 mM, but not 0.1 mM) increased hippocampal ACh levels; however, this effect was relatively insensitive to blockade by co-perfusion of either mecamylamine (100 microM) or SCH-23390 (10 microM). These results suggest that nicotine-induced hippocampal ACh release occurs by two distinct mechanisms: (1) activation of nAChRs outside the hippocampus leading to DA release and subsequent ACh release involving a permissive DA synapse, and (2) direct action of nicotine within the hippocampus leading to ACh release via non-DA-ergic mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455300      PMCID: PMC1760670          DOI: 10.1038/sj.bjp.0702683

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Local alpha-bungarotoxin-sensitive nicotinic receptors modulate hippocampal norepinephrine release by systemic nicotine.

Authors:  Y Fu; S G Matta; B M Sharp
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

Review 2.  Presynaptic nicotinic ACh receptors.

Authors:  S Wonnacott
Journal:  Trends Neurosci       Date:  1997-02       Impact factor: 13.837

3.  Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex.

Authors:  K L Summers; W R Kem; E Giacobini
Journal:  Jpn J Pharmacol       Date:  1997-06

4.  Pharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes.

Authors:  G I Wilkie; P Hutson; J P Sullivan; S Wonnacott
Journal:  Neurochem Res       Date:  1996-09       Impact factor: 3.996

5.  Origin of dopaminergic innervation of the rat hippocampal formation.

Authors:  B Scatton; H Simon; M Le Moal; S Bischoff
Journal:  Neurosci Lett       Date:  1980-06       Impact factor: 3.046

6.  Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities.

Authors:  G K Wilcock; M M Esiri; D M Bowen; C C Smith
Journal:  J Neurol Sci       Date:  1982-12       Impact factor: 3.181

7.  Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats.

Authors:  D L Marshall; P H Redfern; S Wonnacott
Journal:  J Neurochem       Date:  1997-04       Impact factor: 5.372

8.  Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain--an in vivo microdialysis study.

Authors:  Y Tani; K Saito; M Imoto; T Ohno
Journal:  Eur J Pharmacol       Date:  1998-06-19       Impact factor: 4.432

9.  Dopaminergic control of the septal-hippocampal cholinergic pathway.

Authors:  S E Robinson; D Malthe-Sørenssen; P L Wood; J Commissiong
Journal:  J Pharmacol Exp Ther       Date:  1979-03       Impact factor: 4.030

10.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

Authors:  E K Perry; B E Tomlinson; G Blessed; K Bergmann; P H Gibson; R H Perry
Journal:  Br Med J       Date:  1978-11-25
View more
  13 in total

1.  Nicotine exposure does not alter plasma to brain choline transfer.

Authors:  Paul R Lockman; Julie Gaasch; Ghia McAfee; Thomas J Abbruscato; Cornelis J Van der Schyf; David D Allen
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

2.  In vivo effects of the anatoxin-a on striatal dopamine release.

Authors:  F Campos; R Durán; L Vidal; L R F Faro; M Alfonso
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

3.  3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Authors:  Sunila G Nair; Gary A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

4.  Replication and extension of association of choline acetyltransferase with nicotine dependence in European and African American smokers.

Authors:  Jinxue Wei; Jennie Z Ma; Thomas J Payne; Wenyan Cui; Riju Ray; Nandita Mitra; Caryn Lerman; Ming D Li
Journal:  Hum Genet       Date:  2010-04-10       Impact factor: 4.132

5.  Nicotinic and muscarinic agonists and acetylcholinesterase inhibitors stimulate a common pathway to enhance GluN2B-NMDAR responses.

Authors:  Masaru Ishibashi; Yoshihiko Yamazaki; Ricardo Miledi; Katumi Sumikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

6.  The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release.

Authors:  Mei Huang; Anna R Felix; Sunoh Kwon; David Lowe; Tanya Wallace; Luca Santarelli; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2013-12-07       Impact factor: 4.530

7.  The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

Authors:  Mei Huang; Anna R Felix; Dorothy G Flood; Chaya Bhuvaneswaran; Dana Hilt; Gerhard Koenig; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

8.  Local perfusion of nicotine differentially modulates somatodendritic dopamine release in the rat ventral tegmental area after nicotine preexposure.

Authors:  S Rahman; J Zhang; W A Corrigall
Journal:  Neurochem Res       Date:  2004-09       Impact factor: 3.996

Review 9.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

10.  Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice.

Authors:  K Yano; K Koda; Y Ago; H Kobayashi; T Kawasaki; K Takuma; T Matsuda
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.